Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181282 | 0.81 | RIPK1 (0.61) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL4765237 | 0.77 | RIPK1 (0.61) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL1516186 | 0.77 | RIPK1 (0.71) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL30471275 | 0.77 | RIPK1 (0.61) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL28707389 | 0.76 | RIPK1 (0.59) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL16644093 | 0.76 | RIPK1 (0.69) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL432436 | 0.76 | RIPK1 (0.69) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL10990271 | 0.75 | RIPK1 (0.68) | RIPK1MMP8GAAOPRK1SMN1; SMN2 | |
| SCHEMBL16714720 | 0.75 | GAA (0.66) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL2636120 | 0.75 | GAA (0.66) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| EP-2222665-A1 | AZETIDINES AS EP2 ANTAGONISTS | Pfizer Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009063365-A1 | AZETIDINES AS EP2 ANTAGONISTS | PFIZER LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009063365-A1 | AZETIDINES AS EP2 ANTAGONISTS | PFIZER LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008139287-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256109-A1 | Azetidines As EP2 Antagonists | PTGER2, PTGER1, PTGDR2 | RIPK1 4277/4885MMP8 2299/4885GAA 4531/4885 |
| US-20080280877-A1 | Azetidines | PTGER2, PTGER1, PTGDR2 | RIPK1 4559/4885MMP8 1836/4885GAA 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.